578-28-9

Basic information

• Product Name: 4-CHLORO-2,5-DIFLUORONITROBENZENE
• Synonyms: 4-CHLORO-2,5-DIFLUORONITROBENZENE;1-chloro-2,5-difluoro-4-nitrobenzene
• CAS NO: 578-28-9
• Molecular Formula: C₆H₂ClF₂NO₂
• Molecular Weight: 193.54
• Mol File: 578-28-9.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 248.1°C at 760 mmHg
• Flash Point: 103.8°C
• Appearance: /
• Density: 1.591g/cm³
• Vapor Pressure: 0.039mmHg at 25°C
• Refractive Index: 1.531
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: 4-CHLORO-2,5-DIFLUORONITROBENZENE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-CHLORO-2,5-DIFLUORONITROBENZENE(578-28-9)
• EPA Substance Registry System: 4-CHLORO-2,5-DIFLUORONITROBENZENE(578-28-9)

Safety Data

• Hazardous Substances Data: 578-28-9(Hazardous Substances Data)

Usage

General Description

4-Chloro-2,5-difluoronitrobenzene is a kind of organic compound that falls under the category of aromatic halogen compounds. The molecular formula of the chemical is C6H2ClF2NO2 and it has a molecular weight of 195.54 g/mol. It typically manifests in the form of a light yellow liquid and is characterized by a strong, pungent odor. Due to its chemical properties, it is predominantly used in various industrial processes and laboratory research. Given its possible impact on health and the environment, it should be handled with appropriate safety measures in compliant with the designated safety guidelines. The handling and disposal of 4-Chloro-2,5-difluoronitrobenzene should be done under the supervision of trained professionals to avoid potential hazards.

InChI:InChI=1/C6H2ClF2NO2/c7-3-1-5(9)6(10(11)12)2-4(3)8/h1-2H

Upstream product

• 1542-36-5 2,5-difluoro-4-nitroaniline 
• 2367-91-1 1-chloro-2,5-difluorobenzene 
• 540-36-3 para-difluorobenzene 

Downstream Products

• 2105-61-5 1,2,4-trifluoro-5-nitrobenzene 
• 135861-04-0 5-chloro-n-cyclopropyl-4-fluoro-2-nitroaniline 
• 413597-24-7 5-chloro-4-fluoro-2-nitro-N-propylaniline 
• 413597-34-9 (4-fluoro-5-morpholin-4-yl-2-nitro-phenyl)-propyl-amine 
• 139495-71-9 N¹-Cyclopropyl-4-fluoro-5-(4-methyl-piperazin-1-yl)-benzene-1,2-diamine 
• 135861-05-1 4-<5-cyclopropylamino)-2-fluoro-4-nitrophenyl>piperazine 
• 139495-69-5 1-<5-(cyclopropylamino)-2-fluoro-4-nitrophenyl>-4-methylpiperazine 
• 139495-73-1 tert-butyl 4-<5-cyclopropylamino)-2-fluoro-4-aminophenyl>-1-piperazinecarboxylate 
• 137858-24-3 1-acetyl-4-<5-(cyclopropylamino)-2-fluoro-4-nitrophenyl>piperazine 
• 137858-25-4 tert-butyl 4-<5-cyclopropylamino)-2-fluoro-4-nitrophenyl>-1-piperazinecarboxylate 
• 139495-83-3 N-(benzyloxy)-1-cyclopropyl-5-fluoro-6-(4-methyl-1-piperazinyl)-2-benzimidazole acetamide 
• 139495-79-7 2-(Benzyloxy)-5-cyclopropyl-8-fluoro-7-(4-methyl-1-piperazinyl)1H pyrimido[1,6-a]benzimidazole-1,3(2H,5H)dione 
• 137858-30-1 tert-butyl 4-<2-<<(benzyloxycarbonyl)carbamoyl>methyl>-1-cyclopropyl-5-fluoro-6-benzimidazolyl>-1-piperazinecarboxylate 
• 137858-31-2 tert-butyl 4-[2-(benzyloxy)-5-cyclopropyl-8-fluoro-1,2,3,5-tetrahydro-1,3-dioxopyrimido[1,6-a]benzimidazol-7-yl]-1-piperazinecarboxylate 

Relevant articles and documents

Di- and Trifluorinated 2-Azidobenzimidazole Derivatives: Synthesis, Photooxygenation, and 19F NMR Prediction

The photoreactivity of a series of hitherto unknown, multiply fluorinated 2-azidobenzimidazole derivatives was investigated. The synthesis of the starting material includes regioselective p-defluorination of nitrobenzene derivatives employing Ogoshi's conditions. If the 6-position was unsubstituted, irradiation in the presence of N-protected amino acids at 300 nm (Rayonet) led to the formation of arylesters by oxygenation of the 6-position in good to excellent yields and perfect regioselectivity. We did not observe any displacement of fluoride. If the 6-position itself was fluorinated, alternative positions of the benzene portion were attacked. Mechanistically, the reaction proceeds through ring opening of the singlet nitrene to the cyanodiimine or via the iminobenzimidazolium ion. The availability of a set of fluorinated photo-adducts prompted the quantum chemical calculation of their 19F NMR chemical shifts. Even with the most suitable method investigated (ωB97XD/TApr-cc-pVDZ), deviations of up to 5 ppm from the experimental values were observed, underlining the importance of experimental measurements.

COMPOUNDS WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE

Compounds of formula (I) and salts and solvates are provided: In a first aspect therefore, the invention provides a compound of formula (I) or a salt or solvate thereof: wherein R5 is selected from halogen, C1-6alkyl, C1-6alkyl substituted with one or more fluorine atoms, C1-6 alkoxy, C1-6 alkoxy substituted with one or more fluorine atoms, and cyano; R6 is selected from halogen, C1-6alkyl, C1-6alkyl substituted with one or more fluorine atoms, C3-6cycloalkyl, C3-6cycloalkyl substituted with one or more fluorine atoms, C1-6 alkoxy, C1-6 alkoxy substituted with one or more fluorine atoms, and cyano; and Q is hydrogen or C 1-6 alkyl. The compounds are M1 agonists and are useful for therapy, for example in the treatment of psychotic disorders and cognitive impairment.

Alkyl, azido, alkoxy, and fluoro-substituted and fused quinoxalinediones

Methods of treating or preventing neuronal loss associated with stroke, ischemia, CNS trauma, hypoglycemia, and surgery, as well as treating neurodegenerative diseases including Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's disease, and Down's syndrome, treating or preventing the adverse consequences of the hyperactivity of the excitatory amino acids, as well as treating anxiety, chronic pain, convulsions, and inducing anesthesia are disclosed by administering to an animal in need of such treatment an alkyl or azido-substituted 1,4-dihydroquinoxaline-2,3-dione or pharmaceutically acceptable salts thereof, which have high binding to the glycine receptor.